date:Mar 12, 2013
ncer cells from ejecting filamin A. This means that when used in conjunction with hormone deprivation therapy, GCP could be used to kill prostate cancer in patients suffering from the most dangerous form of the disease. At the very least, GCP could be expected to improve the effectiveness of androgen deprivation treatment and extend the life of patients with metastatic prostate cancer.
Ideally, GCP could also reduce the length of time that patients need to be on hormone deprivation therapy, whi